Market News AIOpen the app

IMRX stock news · Immuneering Corporation

Stories about Immuneering Corporation (IMRX) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for IMRX

Follow Immuneering Corporation (IMRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IMRX
Free on the App Store and Google Play, or on the web.
  1. Nov 20, 2026, 9:05 AM ET · New boss

    Andrew Gengos, CFO of Immuneering Corporation, bought $90,000 worth of company stock.

    Good for IMRX

    Immuneering's chief financial officer Andrew Gengos bought $90,000 of shares at $3.58 each. It is a modest positive sign of leadership confidence, not proof of better results.

  2. Nov 19, 2026, 9:16 AM ET · Market

    Immuneering showed new research on how atebimetinib could work well with other treatments for pancreatic cancer.

    Good for IMRX

    Immuneering reported promising early results for atebimetinib combinations, including in a pancreatic cancer model. This supports its treatment program, but does not show whether the drug works in people.